During the last session, Cue Biopharma Inc (NASDAQ:CUE)’s traded shares were 1.05 million, with the beta value of the company hitting 1.93. At the end of the trading day, the stock’s price was $1.33, reflecting an intraday gain of 10.37% or $0.12. The 52-week high for the CUE share is $3.25, that puts it down -144.36 from that peak though still a striking 66.17% gain since the share price plummeted to a 52-week low of $0.45. The company’s market capitalization is $80.08M, and the average intraday trading volume over the past 10 days was 1.87 million shares, and the average trade volume was 577.01K shares over the past three months.
Cue Biopharma Inc (CUE) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CUE has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cue Biopharma Inc (NASDAQ:CUE) trade information
Cue Biopharma Inc (CUE) registered a 10.37% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.37% in intraday trading to $1.33, hitting a weekly high. The stock’s 5-day price performance is 62.35%, and it has moved by 125.65% in 30 days. Based on these gigs, the overall price performance for the year is -37.85%. The short interest in Cue Biopharma Inc (NASDAQ:CUE) is 3.8 million shares and it means that shorts have 8.62 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 77.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $7 respectively. As a result, CUE is trading at a discount of -426.32% off the target high and -50.38% off the low.
Cue Biopharma Inc (CUE) estimates and forecasts
Statistics show that Cue Biopharma Inc has outperformed its competitors in share price, compared to the industry in which it operates. Cue Biopharma Inc (CUE) shares have gone down -24.43% during the last six months, with a year-to-date growth rate more than the industry average at 23.42% against 17.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 20.80% this quarter and then jump 41.40% in the quarter after that. In the rating firms’ projections, revenue will increase 102.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 1.52M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 5.23M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.13M and 1.82M respectively. In this case, analysts expect current quarter sales to grow by 34.50% and then jump by 187.20% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 10.55%. While earnings are projected to return 37.16% in 2024.
CUE Dividends
Cue Biopharma Inc is due to release its next quarterly earnings in November. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cue Biopharma Inc (NASDAQ:CUE)’s Major holders
Cue Biopharma Inc insiders own 0.55% of total outstanding shares while institutional holders control 26.61%, with the float percentage being 26.76%. BLEICHROEDER LP is the largest shareholder of the company, while 94.0 institutions own stock in it. As of 2024-06-30, the company held over 2.86 million shares (or 5.7849% of all shares), a total value of $3.55 million in shares.
The next largest institutional holding, with 2.4 million shares, is of SLATE PATH CAPITAL LP’s that is approximately 4.8567% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.98 million.
